Methyl-glyoxal bis guanyl hydrazone (methyl-GAG, MGBG) in lymphoma and Hodgkin's disease
- 23 Downloads
The Southwest Oncology Group has evaluated methyl-GAG on a weekly schedule among patients with lymphoma and Hodgkin's disease. Among 56 fully and partially evaluable patients responses were seen in 3 of 10 patients with Hodgkin's disease and 11 of 46 patients with lymphoma. Toxicity was acceptable. Methyl-GAG has significant antitumor activity among this group of heavily pretreated patients. Additional trials of methyl-GAG in combination with other agents are underway.
Key wordsmethyl-GAG MGBG methyl-GAG in lymphoma
Unable to display preview. Download preview PDF.
- 1.Knight WA III, Livingston RB, Fabian C, Costanzi J: Phase I–II trial of methyl-GAG: A Southwest Oncology Group pilot study. Cancer Treat Rep 63:1933–1937, 1979Google Scholar
- 2.Warrell RP, Burcheval JH: Methyl glyoxal bis guanyl hydrazone (methyl-GAG): Current status and future prospects. J Clin Oncol 1:52–65, 1983Google Scholar
- 3.Warrell RP, Burton JL, Kempin SJ, Lacker MJ, Straus DJ, Young CW: Effectiveness of methyl-GAG in patients with advanced malignant lymphoma. Blood 57:1011–1014, 1981Google Scholar
- 4.Myers JW, Knight WA III, Livingston RB, Fabian C, Costanzi J: Phase I–II, trial of methyl-GAG in advanced colon cancer. A Southwest Oncology Group pilot study. Cancer Clin Trials 4:227–280, 1981Google Scholar
- 5.Knight WA III, Loesch DM, Leichman L, Fabian C, O'Bryan R: Methyl-GAG in advanced colon cancer. A phase II trial of the Southwest Oncology Group. Cancer Treat Rep 66: 2099–2100, 1982Google Scholar